24/7 Market News Snapshot 25 November, 2024 – Stereotaxis, Inc. Common Stock (NYSE:STXS)

November 25, 2024

DENVER, Colo., 25 November, 2024 (247marketnews.com) – (NYSE:STXS) are discussed in this article.
Stereotaxis, Inc. is experiencing significant upward momentum as its stock trades at $2.268, reflecting a notable increase of 10.63% from a previous close of $2.050. The current trading volume has reached 1.06 million shares, indicating heightened investor interest and confidence in the company. Traders are advised to monitor resistance levels around $2.30 and support near $2.15, as sustained volume and upward movement may signal further bullish opportunities for Stereotaxis in the near term.

In a groundbreaking development, Stereotaxis, in partnership with Shanghai MicroPort EP Medtech Co., Ltd., has received regulatory approval from the National Medical Products Administration (NMPA) for its Genesis RMN® System. This milestone introduces innovative robotic technology to the electrophysiology field, enabling minimally invasive procedures that enhance patient care. The commercial launch is set to commence through MicroPort EP’s dedicated sales team, furthering the collaboration initiated in August 2021, which integrates Stereotaxis’ robotic system with MicroPort EP’s advanced Columbus™ 3D mapping technology.

Dr. Yiyong Sun, President of MicroPort EP, emphasized the importance of this partnership, expressing pride in the ability to bring the Genesis System to market, designed to offer the electrophysiology community cutting-edge solutions. Meanwhile, David Fischel, Chairman and CEO of Stereotaxis, highlighted that receiving NMPA clearance is a significant achievement, reinforcing the company’s commitment to innovation which aims to significantly improve patient outcomes in cardiovascular care.

With prior FDA clearance and CE marking, the Genesis RMN® System is already deployed in various regions worldwide, positively affecting thousands of patients and demonstrating Stereotaxis’ ongoing commitment to advancing medical technology. The partnership with MicroPort EP signifies a shared vision of innovation and excellence that promises to transform cardiac procedures globally.

Related news for (STXS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.